Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies
Abstract Aims The ultra-low-temperature cryoablation (ULTC) ablation system using −196°C N2 cryogen has been reported to create lesions with freeze duration–dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evalua...
Saved in:
Published in | Europace (London, England) Vol. 26; no. 4 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
UK
Oxford University Press
30.03.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Aims
The ultra-low-temperature cryoablation (ULTC) ablation system using −196°C N2 cryogen has been reported to create lesions with freeze duration–dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs).
Methods and results
This prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1–9) to 0, IQR (0–2).
Conclusion
In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy.
Clinical Trial Registration
NCT04893317.
Graphical Abstract
Graphical Abstract |
---|---|
AbstractList | AIMSThe ultra-low-temperature cryoablation (ULTC) ablation system using -196°C N2 cryogen has been reported to create lesions with freeze duration-dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs).METHODS AND RESULTSThis prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1-9) to 0, IQR (0-2).CONCLUSIONIn this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy.CLINICAL TRIAL REGISTRATIONNCT04893317. Abstract Aims The ultra-low-temperature cryoablation (ULTC) ablation system using −196°C N2 cryogen has been reported to create lesions with freeze duration–dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs). Methods and results This prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1–9) to 0, IQR (0–2). Conclusion In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy. Clinical Trial Registration NCT04893317. Abstract Aims The ultra-low-temperature cryoablation (ULTC) ablation system using −196°C N2 cryogen has been reported to create lesions with freeze duration–dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs). Methods and results This prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1–9) to 0, IQR (0–2). Conclusion In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy. Clinical Trial Registration NCT04893317. Graphical Abstract Graphical Abstract Graphical Abstract The ultra-low-temperature cryoablation (ULTC) ablation system using -196°C N2 cryogen has been reported to create lesions with freeze duration-dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs). This prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1-9) to 0, IQR (0-2). In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy. NCT04893317. |
Author | Reddy, Vivek Y Darma, Angeliki Neuzil, Petr Dinov, Borislav Essebag, Vidal Balt, Jippe Sacher, Frederic Verma, Atul Dyrda, Katia De Potter, Tom Grigorov, Ilya Boersma, Lucas Arya, Arash |
Author_xml | – sequence: 1 givenname: Atul orcidid: 0000-0002-1020-9727 surname: Verma fullname: Verma, Atul email: atul.verma@mcgill.ca – sequence: 2 givenname: Vidal orcidid: 0000-0003-0107-5197 surname: Essebag fullname: Essebag, Vidal – sequence: 3 givenname: Petr orcidid: 0000-0003-4334-8165 surname: Neuzil fullname: Neuzil, Petr – sequence: 4 givenname: Katia orcidid: 0000-0002-0171-9311 surname: Dyrda fullname: Dyrda, Katia – sequence: 5 givenname: Jippe orcidid: 0000-0002-7880-3730 surname: Balt fullname: Balt, Jippe – sequence: 6 givenname: Borislav orcidid: 0000-0003-1104-8491 surname: Dinov fullname: Dinov, Borislav – sequence: 7 givenname: Angeliki orcidid: 0000-0003-4756-2775 surname: Darma fullname: Darma, Angeliki – sequence: 8 givenname: Arash orcidid: 0009-0005-7610-9314 surname: Arya fullname: Arya, Arash – sequence: 9 givenname: Frederic orcidid: 0000-0001-8348-9320 surname: Sacher fullname: Sacher, Frederic – sequence: 10 givenname: Vivek Y orcidid: 0000-0002-5638-4993 surname: Reddy fullname: Reddy, Vivek Y – sequence: 11 givenname: Lucas orcidid: 0000-0003-4591-4220 surname: Boersma fullname: Boersma, Lucas – sequence: 12 givenname: Ilya surname: Grigorov fullname: Grigorov, Ilya – sequence: 13 givenname: Tom orcidid: 0000-0003-1424-114X surname: De Potter fullname: De Potter, Tom email: tom.de.potter@olvz-aalst.be |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38582974$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUctu1TAQtVAr-oA9K-QlEgr1I082CF21gFSJTWEbTZwJMUriYDut8l98IBPubWlXSJY8mjnnzJyZM3Y0uQkZeyXFOykqfYGLdzMYpABQFPkzdiozrRIlKnVEsaiqJJOqOmFnIfwUQhSqyp6zE11mpaqK9JT93vnVmcVj8v3mPY898gAdxpXD1HLsOjTR3uKEIXDX8WWIHpLB3SURxxk9RGJyQxLQDBCtmzbU6CY3Oj_31nDiRm_NMoDnEUy_GvCtBW4nPhOBqoHf2dhzG0wPOBJl60w-k3-Zvxw3ruQ19hbDC3bcwRDw5eE_Z9-uLm92n5Prr5--7D5eJ0aXeUwUbaaURgh6kMuySKXOZNaVEjpFKciQHGZN07QStEpFjka1bdUq1RbQCn3OPux156UZsTWbFxjq2dsR_Fo7sPXTymT7-oe7rbfFl1W-Kbw5KHj3a8EQ65Fs4TDAhG4JtRY6VSkBc4KKPdR4F4LH7qGPFJugru-vXR-uTZTXj-d7INyflwBv9wC3zP-X-wMO4cIg |
Cites_doi | 10.3390/jcm10143021 10.1016/j.hrthm.2023.03.395 10.1016/j.jacc.2015.11.041 10.1093/eurheartj/ehac262 10.1007/s10840-023-01614-9 10.1161/CIRCULATIONAHA.122.059598 10.1161/CIRCEP.121.010347 10.1007/s00392-022-02090-3 10.1016/S0140-6736(09)61755-4 10.1016/j.hrthm.2020.04.028 10.1016/j.hrthm.2019.03.002 10.1016/j.jacep.2017.01.020 10.1056/NEJMoa065457 10.1161/CIRCULATIONAHA.122.060039 10.1161/01.CIR.101.11.1288 10.1016/B978-1-4377-1615-3.00009-5 10.1161/CIRCEP.110.959957 10.1161/CIRCULATIONAHA.119.043400 10.1111/jce.14907 10.1007/s10840-021-00948-6 10.1016/j.jacep.2022.05.017 10.1161/CIRCULATIONAHA.108.788604 10.1093/eurheartj/suab082 10.1016/j.hroo.2022.12.005 10.1016/j.hroo.2020.06.006 10.1016/j.jacep.2019.09.015 10.1016/j.jacep.2022.11.017 10.1161/JAHA.113.000072 |
ContentType | Journal Article |
Copyright | The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. 2024 The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. |
Copyright_xml | – notice: The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. 2024 – notice: The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. |
DBID | TOX CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1093/europace/euae076 |
DatabaseName | Oxford University Press Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: TOX name: Oxford University Press Open Access url: https://academic.oup.com/journals/ sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-2092 |
ExternalDocumentID | 10_1093_europace_euae076 38582974 10.1093/europace/euae076 |
Genre | Clinical Trial Multicenter Study Journal Article |
GrantInformation_xml | – fundername: Adagio Medical Inc – fundername: ; |
GroupedDBID | --- --K .2P .I3 .XZ .ZR 0R~ 1B1 1TH 29G 2WC 4.4 48X 53G 5GY 5VS 5WA 6PF 70D AABZA AACZT AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AASNB AAUAY AAUQX AAVAP AAWTL ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABQTQ ABWST ABXVV ABZBJ ACGFS ACPRK ACUFI ACUTO ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADJQC ADOCK ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHXPO AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C1A CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IHE IOX J21 KBUDW KOP KQ8 KSI KSN M-Z M41 M49 MHKGH N9A NGC NOMLY NOYVH NQ- NTWIH NU- O0~ O9- OAUYM OAWHX ODMLO OJQWA OJZSN OK1 OPAEJ OVD P2P PAFKI PEELM PQQKQ Q1. Q5Y RD5 RHF RIG ROL ROX RPM RPZ RUSNO RW1 RXO SEL SV3 TCURE TEORI TJX TOX TR2 UHS VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c386t-2ace81c00c00a6187413515f81af200aa5eeff5bbbd1a32406ec2dd9d22d7ad03 |
IEDL.DBID | RPM |
ISSN | 1099-5129 |
IngestDate | Tue Sep 17 21:29:42 EDT 2024 Sun Jul 21 07:11:48 EDT 2024 Fri Aug 23 01:57:57 EDT 2024 Sat Sep 28 08:10:46 EDT 2024 Wed Aug 28 03:15:37 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Ventricular tachycardia Clinical trial Cryoablation Ultra-low Ablation Outcomes |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c386t-2ace81c00c00a6187413515f81af200aa5eeff5bbbd1a32406ec2dd9d22d7ad03 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 Conflict of interest: A.V. reports being a consultant for Biosense Webster, Medtronic, Adagio Medical, Medlumics, and Abbott. L.B. reports being a consultant for Medtronic, Boston Scientific, and Adagio Medical. All fees go to the cardiology department. V.E. is supported by a Clinical Research Scholar Award from the Fonds de Recherche du Quebec Santé (FRQS) and reports honoraria from Abbott, Biosense Webster, Boston Scientific, and Medtronic. V.Y.R. reports serving as a consultant to Adagio Medical, unrelated to this manuscript. V.Y.R. has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera-Medtronic, Anumana, Apama Medical-Boston Scientific, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT/AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNovA EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics-Medtronic, EpiEP, Eximo, Farapulse-Boston Scientific, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, and Valcare, unrelated to this work. V.R. has served as a consultant for Abbott, AtriAN, Biosense-Webster, BioTel Heart, Biotronik, Boston Scientific, Cairdac, Cardiofocus, Cardionomic, CoreMap, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Novartis, Philips, and Pulse Biosciences, unrelated to this work, V.R. has equity in Atraverse, Manual Surgical Sciences, Newpace, Nyra Medical, Surecor, and Vizaramed. I.G. is an employee of Adagio Medical. T.D.P. reports receiving institutional payments related to study activities from Adagio Medical, unrelated to this manuscript and reports receiving institutional payments for consultancy from Abbott, Boston Scientific, GE, J&J, and Medlumics. All remaining authors have declared no conflicts of interest. |
ORCID | 0000-0003-4591-4220 0000-0003-0107-5197 0000-0003-4756-2775 0000-0003-1104-8491 0000-0001-8348-9320 0000-0003-1424-114X 0000-0003-4334-8165 0009-0005-7610-9314 0000-0002-5638-4993 0000-0002-0171-9311 0000-0002-7880-3730 0000-0002-1020-9727 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10998960/ |
PMID | 38582974 |
PQID | 3034246036 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10998960 proquest_miscellaneous_3034246036 crossref_primary_10_1093_europace_euae076 pubmed_primary_38582974 oup_primary_10_1093_europace_euae076 |
PublicationCentury | 2000 |
PublicationDate | 2024-03-30 |
PublicationDateYYYYMMDD | 2024-03-30 |
PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | UK |
PublicationPlace_xml | – name: UK – name: England |
PublicationTitle | Europace (London, England) |
PublicationTitleAlternate | Europace |
PublicationYear | 2024 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Muser (2024042910374132700_euae076-B28) 2017; 3 De Potter (2024042910374132700_euae076-B10) 2023; 9 Reddy (2024042910374132700_euae076-B24) 2007; 357 Stevenson (2024042910374132700_euae076-B14) 2008; 118 Guandalini (2024042910374132700_euae076-B4) 2019; 5 Marchlinski (2024042910374132700_euae076-B7) 2000; 101 Rattan (2024042910374132700_euae076-B27) 2020; 6 Hutchinson (2024042910374132700_euae076-B8) 2011; 4 John (2024042910374132700_euae076-B30) 2020; 1 Scott (2024042910374132700_euae076-B1) 2023; 4 Molitor (2024042910374132700_euae076-B3) 2021; 10 Della Bella (2024042910374132700_euae076-B19) 2022; 145 Igarashi (2024042910374132700_euae076-B13) 2020; 17 Bourier (2024042910374132700_euae076-B6) 2021; 32 Marchlinski (2024042910374132700_euae076-B15) 2016; 67 Cronin (2024042910374132700_euae076-B23) 2020; 17 Eckardt (2024042910374132700_euae076-B2) 2023; 112 Tokuda (2024042910374132700_euae076-B16) 2013; 2 (2024042910374132700_euae076-B17) 2022 Tan (2024042910374132700_euae076-B26) 2023 Zeppenfeld (2024042910374132700_euae076-B21) 2022; 43 Packer (2024042910374132700_euae076-B22) 2022; 15 De Potter (2024042910374132700_euae076-B9) 2022; 8 Bianchi (2024042910374132700_euae076-B29) 2021; 23 Ding (2024042910374132700_euae076-B12) 2022; 63 Tung (2024042910374132700_euae076-B18) 2022; 145 Littrup (2024042910374132700_euae076-B5) 2011 Kuck (2024042910374132700_euae076-B25) 2010; 375 Dewland (2024042910374132700_euae076-B11) 2023; 20 Willems (2024042910374132700_euae076-B20) 2020; 141 |
References_xml | – volume: 10 start-page: 3021 year: 2021 ident: 2024042910374132700_euae076-B3 article-title: Swiss national registry on catheter ablation procedures: changing trends over the last 20 years publication-title: J Clin Med doi: 10.3390/jcm10143021 contributor: fullname: Molitor – volume: 20 start-page: S92 year: 2023 ident: 2024042910374132700_euae076-B11 article-title: AB-452672-2 ultra-low temperature cryoablation versus ultra-low temperature cryoablation combined with pulsed field ablation in a swine ventricular infarct model publication-title: Heart Rhythm doi: 10.1016/j.hrthm.2023.03.395 contributor: fullname: Dewland – volume: 67 start-page: 674 year: 2016 ident: 2024042910374132700_euae076-B15 article-title: Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular tachycardia: post-approval THERMOCOOL VT trial publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2015.11.041 contributor: fullname: Marchlinski – year: 2022 ident: 2024042910374132700_euae076-B17 – volume: 43 start-page: 3997 year: 2022 ident: 2024042910374132700_euae076-B21 article-title: 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death publication-title: Eur Heart J doi: 10.1093/eurheartj/ehac262 contributor: fullname: Zeppenfeld – year: 2023 ident: 2024042910374132700_euae076-B26 article-title: Thirty-day readmission after catheter ablation for ventricular tachycardia: associated factors and outcomes publication-title: J Interv Card Electrophysiol doi: 10.1007/s10840-023-01614-9 contributor: fullname: Tan – volume: 145 start-page: 1829 year: 2022 ident: 2024042910374132700_euae076-B19 article-title: Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? Results from the multicenter randomized PARTITA trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.122.059598 contributor: fullname: Della Bella – volume: 15 start-page: e010347 year: 2022 ident: 2024042910374132700_euae076-B22 article-title: Ablation of refractory ventricular tachycardia using intramyocardial needle delivered heated saline-enhanced radiofrequency energy: a first-in-man feasibility trial publication-title: Circ Arrhythm Electrophysiol doi: 10.1161/CIRCEP.121.010347 contributor: fullname: Packer – volume: 112 start-page: 784 year: 2023 ident: 2024042910374132700_euae076-B2 article-title: 10-year follow-up of interventional electrophysiology: updated German survey during the COVID-19 pandemic publication-title: Clin Res Cardiol doi: 10.1007/s00392-022-02090-3 contributor: fullname: Eckardt – volume: 375 start-page: 31 year: 2010 ident: 2024042910374132700_euae076-B25 article-title: Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(09)61755-4 contributor: fullname: Kuck – volume: 17 start-page: 1500 year: 2020 ident: 2024042910374132700_euae076-B13 article-title: Acute and long-term results of bipolar radiofrequency catheter ablation of refractory ventricular arrhythmias of deep intramural origin publication-title: Heart Rhythm doi: 10.1016/j.hrthm.2020.04.028 contributor: fullname: Igarashi – volume: 17 start-page: e2 year: 2020 ident: 2024042910374132700_euae076-B23 article-title: 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias publication-title: Heart Rhythm doi: 10.1016/j.hrthm.2019.03.002 contributor: fullname: Cronin – volume: 3 start-page: 767 year: 2017 ident: 2024042910374132700_euae076-B28 article-title: Long-term outcomes of catheter ablation of electrical storm in nonischemic dilated cardiomyopathy compared with ischemic cardiomyopathy publication-title: JACC Clin Electrophysiol doi: 10.1016/j.jacep.2017.01.020 contributor: fullname: Muser – volume: 357 start-page: 2657 year: 2007 ident: 2024042910374132700_euae076-B24 article-title: Prophylactic catheter ablation for the prevention of defibrillator therapy publication-title: N Engl J Med doi: 10.1056/NEJMoa065457 contributor: fullname: Reddy – volume: 145 start-page: 1839 year: 2022 ident: 2024042910374132700_euae076-B18 article-title: First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.122.060039 contributor: fullname: Tung – volume: 101 start-page: 1288 year: 2000 ident: 2024042910374132700_euae076-B7 article-title: Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy publication-title: Circulation doi: 10.1161/01.CIR.101.11.1288 contributor: fullname: Marchlinski – start-page: 107 volume-title: Cryoablation of Cardiac Arrhythmias year: 2011 ident: 2024042910374132700_euae076-B5 doi: 10.1016/B978-1-4377-1615-3.00009-5 contributor: fullname: Littrup – volume: 6 start-page: 29 year: 2020 ident: 2024042910374132700_euae076-B27 article-title: Causes and predictors of hospital readmissions after ischemic ventricular tachycardia ablation publication-title: Int J Med Res Prof contributor: fullname: Rattan – volume: 4 start-page: 49 year: 2011 ident: 2024042910374132700_euae076-B8 article-title: Endocardial unipolar voltage mapping to detect epicardial ventricular tachycardia substrate in patients with nonischemic left ventricular cardiomyopathy publication-title: Circ Arrhythm Electrophysiol doi: 10.1161/CIRCEP.110.959957 contributor: fullname: Hutchinson – volume: 141 start-page: 1057 year: 2020 ident: 2024042910374132700_euae076-B20 article-title: Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable defibrillator (BERLIN VT): a multicenter randomized trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.043400 contributor: fullname: Willems – volume: 32 start-page: 570 year: 2021 ident: 2024042910374132700_euae076-B6 article-title: Ultralow temperature cryoablation: safety and efficacy of preclinical atrial and ventricular lesions publication-title: J Cardiovasc Electrophysiol doi: 10.1111/jce.14907 contributor: fullname: Bourier – volume: 63 start-page: 59 year: 2022 ident: 2024042910374132700_euae076-B12 article-title: Complication rates following ventricular tachycardia ablation in ischaemic and non-ischaemic cardiomyopathies: a systematic review publication-title: J Interv Card Electrophysiol doi: 10.1007/s10840-021-00948-6 contributor: fullname: Ding – volume: 8 start-page: 1034 year: 2022 ident: 2024042910374132700_euae076-B9 article-title: Ultra-low temperature cryoablation for atrial fibrillation: primary outcomes for efficacy and safety: the cryocure-2 study publication-title: JACC Clin Electrophysiol doi: 10.1016/j.jacep.2022.05.017 contributor: fullname: De Potter – volume: 118 start-page: 2773 year: 2008 ident: 2024042910374132700_euae076-B14 article-title: Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.108.788604 contributor: fullname: Stevenson – volume: 23 start-page: E25 year: 2021 ident: 2024042910374132700_euae076-B29 article-title: Ablation of ventricular tachycardia in 2021 publication-title: Eur Heart J Suppl doi: 10.1093/eurheartj/suab082 contributor: fullname: Bianchi – volume: 4 start-page: 193 year: 2023 ident: 2024042910374132700_euae076-B1 article-title: Contemporary trends in cardiac electrophysiology procedures in the United States, and impact of a global pandemic publication-title: Heart Rhythm O2 doi: 10.1016/j.hroo.2022.12.005 contributor: fullname: Scott – volume: 1 start-page: 290 year: 2020 ident: 2024042910374132700_euae076-B30 article-title: Bipolar ablation’s unique paradigm: duration and power as respectively distinct primary determinants of transmurality and steam pop formation publication-title: Heart Rhythm O2 doi: 10.1016/j.hroo.2020.06.006 contributor: fullname: John – volume: 5 start-page: 1363 year: 2019 ident: 2024042910374132700_euae076-B4 article-title: Ventricular tachycardia ablation: past, present, and future perspectives publication-title: JACC Clin Electrophysiol doi: 10.1016/j.jacep.2019.09.015 contributor: fullname: Guandalini – volume: 9 start-page: 686 year: 2023 ident: 2024042910374132700_euae076-B10 article-title: First-in-human experience with ultra-low temperature cryoablation for monomorphic ventricular tachycardia publication-title: JACC Clin Electrophysiol doi: 10.1016/j.jacep.2022.11.017 contributor: fullname: De Potter – volume: 2 start-page: e000072 year: 2013 ident: 2024042910374132700_euae076-B16 article-title: Acute failure of catheter ablation for ventricular tachycardia due to structural heart disease: causes and significance publication-title: J Am Heart Assoc doi: 10.1161/JAHA.113.000072 contributor: fullname: Tokuda |
SSID | ssj0007295 |
Score | 2.443164 |
Snippet | Abstract
Aims
The ultra-low-temperature cryoablation (ULTC) ablation system using −196°C N2 cryogen has been reported to create lesions with freeze... The ultra-low-temperature cryoablation (ULTC) ablation system using -196°C N2 cryogen has been reported to create lesions with freeze duration-dependent depth... AIMSThe ultra-low-temperature cryoablation (ULTC) ablation system using -196°C N2 cryogen has been reported to create lesions with freeze duration-dependent... Graphical Abstract |
SourceID | pubmedcentral proquest crossref pubmed oup |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
SubjectTerms | Aged Cardiomyopathies - complications Cardiomyopathies - diagnosis Cardiomyopathies - surgery Catheter Ablation - adverse effects Cicatrix - complications Clinical Research Cryosurgery - adverse effects Humans Middle Aged Prospective Studies Tachycardia, Ventricular - diagnosis Tachycardia, Ventricular - etiology Tachycardia, Ventricular - surgery Temperature Treatment Outcome |
Title | Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38582974 https://search.proquest.com/docview/3034246036 https://pubmed.ncbi.nlm.nih.gov/PMC10998960 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBa7eyi9lL6b7QMV9tKDNo5sK3JvJXRZCml7yJbcjJ6sIbaX2KHkf_UHdkaWt0lPpWCMsfWwPSPpk2bmEyEXifbGA_SG3o9rlpmZY9rmBXPcmkRLMRcGY4eXX8X1TfZlna9PiBhjYYLTvtHVZbOpL5vqNvhW3tVmOvqJTb8vF2jNkQC9p6fkdJ6m4xw99r8AF_Ng4ywKhsNZNE7C1H2KfBcwFXVwoVyCPCMHg9FRgNsBzvzbXfJg_Ll6TB5F4Eg_DS_4hJy45il5sIym8Wfk12K7b81u69iP1UcKsI52yrt-T1Vj6eC1ETs22nq620AdbNP-ZMhNFYmVqYEilB684zBVjREPLUiiMhT9IsNiodrSXpnbvQm6RauGRm7WjuKiLq06dMSvIQvW3LQN-3Mn5GnrfRs2Qnbdc3Jz9Xm1uGZxSwZmUil6xuHnyZlJEjiUwP38cIe_3MuZ8tDelModfFGutbYzhVx_whlubWE5t3Nlk_QFOYOK3StCC-EFT0zmjcgzr7lWAL_m0CFIaRMv1YR8GGVT3g3MG-VgMU_LUY5llOOEXIDw_iHZ-1G6JbQiNI2oxrW7rkyRCTETMJxPyMtB2veloemUw7RrQuSRHtwnQIbu4yeguIGpe1TU8__P-po85ICjQhhk8oac9dudews4qNfvgtrDefVt_RsuqRQs |
link.rule.ids | 230,315,733,786,790,891,1611,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGP00hgS8jOugXI20Fx7cpm7iJryhiqnAOvHQwd4iX7WIJpmaRFP5XfxAPjvJaPcESH2IGjsX-dg-zne-Y4CjQFplkXrj6MckDdXYUKmjhBqmVSBjPuXK5Q4vTvn8LPx8Hp3vAe9zYbxoX8lsWKzyYZFdeG3lZa5GvU5s9HUxc9GcGKn36Bbcxg7Lpv0qvRuBkTBGPsqZJNRNaF14EhfvI-d4gYtRgwfCBM5pZGs62klx22KaNwWTWzPQ8X343j97Kzz5MWxqOVQ_b9g6_vvLPYCDjpSSD-35h7BnikdwZ9GF3R_Dr9l6U6pmbei35XuClJFUwpp6Q0ShSasI6QZNUlrSrPDp6aq8os73qjNtJgovIWSrvHOlcpdNUWIrZ4o4zaX_ECnWpBbqYqM8bklWkM73tSLugzHJKifyz7GKu3NRFvTPP75OmW9Kv8myqZ7A2fHH5WxOu-0eqJrEvKYMmyUeqyDAn-Bur0C3e2Bk47Gw2JeFiAy-USSl1GPhfAS5UUzrRDOmp0IHk0PYxxubZ0ASbjkLVGgVj0IrmRRI7aY42MSxDmwsBvCub_X0snX1SNto_CTtEZJ2CBnAEcLiL4q97XGTYg91YRdRmLKp0olzWQw5UoUBPG1xdH01F5ZluKQbQLyDsOsCzv179wzixruA9zh5_v9V38Dd-XJxkp58Ov3yAu4x5Gs-3TJ4Cfv1ujGvkG_V8rXvXL8B3gw1Qw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swGLW2Tqr2su7aZVdP6ssenBAHHNjblC3qLqn60E6V9oB8VdECRAFUZb9rP3DfB6ZL-jRV4gGBDVg-to_5jo8JOQqU0w6oN_R-XLFQjy1TJkqY5UYHKhZToXHt8OJEHJ-HXy-iC6-qrLysstAqGxbLfFhkl622cpXrUa8TG50uZhjNiYF6j1bGje6Se9BoedLP1H0vDKQxaiOdScJwUPMhSpjAj9D1AiakFk6kDdBtZGtI2lnmtsU2b4omt0ah-QH52X9_Jz75NWxqNdS_b1g73q6AD8kDT07pxy7NI3LHFo_J_sKH35-QP7P1ptTN2rIfZx8oUEdaSWfrDZWFoZ0yxHeetHS0WUIJ2LK8Yuh_5c2bqYZHSNUp8DBVjqsqSqjtTFPUXrY_JOWa1lJfbnSLX5oV1Pu_VhR_HNOsQrF_DlnwzUVZsH9X2jxlvinbzZZt9ZSczz-fzY6Z3_aB6UksasahauKxDgI4pMA9A3EXwcjFY-mgTUsZWShRpJQyY4l-gsJqbkxiODdTaYLJM7IHL7bPCU2EEzzQodMiCp3iSgLFm0KnE8cmcLEckPd9zaerzt0j7aLyk7RHSepRMiBHAI3_SPaux04KLRXDL7KwZVOlE3RbDAVQhgE57LB0_TQMz3KY2g1IvIOy6wToAr57B7DTuoH3WHlx-6xvyf7pp3n6_cvJt5fkPgfa1q66DF6RvXrd2NdAu2r1pm1ffwEv-zfD |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cryocure-VT%3A+the+safety+and+effectiveness+of+ultra-low-temperature+cryoablation+of+monomorphic+ventricular+tachycardia+in+patients+with+ischaemic+and+non-ischaemic+cardiomyopathies&rft.jtitle=Europace+%28London%2C+England%29&rft.au=Verma%2C+Atul&rft.au=Essebag%2C+Vidal&rft.au=Neuzil%2C+Petr&rft.au=Dyrda%2C+Katia&rft.date=2024-03-30&rft.issn=1099-5129&rft.eissn=1532-2092&rft.volume=26&rft.issue=4&rft_id=info:doi/10.1093%2Feuropace%2Feuae076&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_europace_euae076 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1099-5129&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1099-5129&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1099-5129&client=summon |